Skip to main content

Pretreatment with sufentanil reduces myoclonus after etomidate

Buy Article:

$43.00 plus tax (Refund Policy)


Myoclonic movements are a common problem during the induction of general anesthesia with etomidate. We investigated the influence of pretreatment with the opioid sufentanil on the incidence of etomidate-induced myoclonus. Methods:

Forty female patients (ASA physical status I–III) were randomly assigned to receive double-blinded either 0.3 µg kg−1 of sufentanil or placebo 150 s before the induction of sleep with 0.3 mg kg−1 of etomidate. The patients were observed for any myoclonic movement. Grade of dizziness, breathing frequency, non-invasive blood pressure and heart rate were measured during the study period. Results:

None of the 20 patients receiving sufentanil had myoclonic movements after the administration of etomidate, whereas 16 patients in the placebo group (80%) experienced such movements (P<0.01). No cases of apnoea before induction of sleep were seen in the sufentanil group. Conclusion:

Sufentanil 0.3 µg kg−1 is an effective and safe drug to reduce myoclonus after etomidate without causing any harmful side-effect.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: adverse effects; anesthetics; etomidate; myoclonus; sufentanil

Document Type: Research Article

Affiliations: 1: Klinik fuer Anesthesiologie und Intensivtherapie, Friedrich-Schiller-Universitaet Jena, Germany, 2: Department of Kinesiology, University of Wisconsin, WI

Publication date: 2003-04-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more